چکیده: (1526 مشاهده)
Introduction: Several vaccine platforms have been designed to elicit an effective immune response against SARS-CoV-2. This study was aimed to evaluate the humoral immune response in Iranian people vaccinated with both inactivated virus vaccines and vector vaccine platforms. Methods: The study enrolled 360 vaccinated individuals with inactivated virus vaccines (BBIBP-CorV and Covaxin) and vector vaccine platforms (AstraZeneca and Sputnik V). Serum samples were collected for each volunteer on days 14 to 21 after vaccination, and anti–SARS-CoV-2 spike receptor-binding domain (RBD) IgG concentrations were analyzed by ELISA. Results: Higher antibody titers were observed in participants vaccinated with vector vaccines compared with those immunized with inactivated virus, especially in subjects who received two doses of AstraZeneca. (AstraZeneca: 204.19 U/mL [95% CI, 175.5-232.2] vs. Sputnik V :114.67 U/mL [95% CI, 99.54-129.8]; P = 0.007). It was also observed that antibody titers were not significantly different between the two groups receiving inactivated vaccines (P = 0.86). Our results indicated that 28% of the population vaccinated with Covaxin and 32% of people vaccinated with BBIBP-CorV showed no response to the vaccine. There was also a statistically insignificant difference between age, BMI, and gender with antibody level in each group of vaccines (P > 0.05). Conclusion: Based on a limited population data , our study showed that the viral vector-based vaccines produced higher levels of neutralized antibodies than the inactivated vaccines, and their rate of non-response was lesser.
نوع مطالعه:
پژوهشي |
موضوع مقاله:
Immune responses tovaccines دریافت: 1401/9/29